Grantham, Mayo, Van Otterloo & Co (GMO)’s Myriad Genetics MYGN Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-34,000	Closed	-$973K	–	736
2019 Q3	$973K	Buy	+34,000	New	+$991K	0.01%	546
2019 Q1	–	Sell	-15,200	Closed	-$442K	–	729
2018 Q4	$442K	Hold	15,200	–	–	﹤0.01%	454
2018 Q3	$699K	Sell	15,200 -3,900	-20%	-$173K	﹤0.01%	414
2018 Q2	$714K	Hold	19,100	–	–	0.01%	421
2018 Q1	$564K	Buy	19,100 +5,100	+36%	+$173K	﹤0.01%	469
2017 Q4	$481K	Buy	+14,000	New	+$472K	﹤0.01%	464

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s MYGN Position: Q4 2019 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Myriad Genetics (MYGN) in Q4 2019, closing a stake of 34,000 shares — an estimated $973K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in MYGN in Q4 2017 and held it in 6 quarters. The position peaked at $973K in Q3 2019. 227 funds tracked by Wall St. Rank hold MYGN as of Q4 2019.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Myriad Genetics position as of Q4 2019 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 34,000 Myriad Genetics shares in Q4 2019, an estimated $973K.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Myriad Genetics in Q4 2017 and held it in 6 quarters.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Myriad Genetics position peaked at $973K in Q3 2019.
227 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2019.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q4 2019, filed 13 Feb 2020.